Back to search results

Pediatric Electrocutaneous Analgesia for Neuropathic Pain

This study is testing a non-invasive treatment called Scrambler Therapy MC-5A Device for children and young adults (ages 5-26) who have neuropathic pain (nerve pain) due to cancer. The therapy uses electrodes placed on the skin to send low-level electrical signals that aim to "scramble" pain messages. The main goal is to see if this therapy can reduce your pain intensity, as measured by pain scales, and potentially decrease your need for pain medications. The study is looking to enroll up to 70 participants. The current status of the study is unclear.

Study design
This is an interventional study planning to enroll up to 70 participants. It will evaluate the Scrambler Therapy MC-5A Device.
What's involved
You would undergo 5 to 10 therapy sessions over 1-2 weeks, with pain assessed before and after each session. You would also complete additional questionnaires and have follow-up assessments at 1, 3, and 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up at 1, 3, and 6 months after the last therapy session to evaluate long-term pain relief and changes in medication use.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07264920

Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic Pain

Not Yet Recruiting
NAAges 5–26InterventionalTreatment
Johns Hopkins University
~70 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Scrambler Therapy MC-5A Device

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in self-reported pain intensity as assessed by the Numerical Rating Scale or the Wong-Baker Faces Pain Scale
Measured over Prior to first therapy session and immediately following last therapy session

Conditions

Neuropathic Pain
Chronic Pain

Explore related trials

Chronic PainMalignant NeoplasmNeuropathic Pain

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Joann Hunsberger, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Joann Hunsberger, MD
[email protected]
410-955-2448
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to verbalize pain scores
Oncology patients with acute and/or chronic pain

Exclusion

Patients with Implantable Devices
Epilepsy
Pregnancy
A history of myocardial infarction or ischemic heart disease within the past six months
History of severe heart arrhythmia or equivalent heart disease
Open Wounds or Infections at site of electrode placement
A history of intolerance to transcutaneous electronic nerve stimulation

What this trial measures

  • Change in self-reported pain intensity as assessed by the Numerical Rating Scale or the Wong-Baker Faces Pain ScalePrior to first therapy session and immediately following last therapy session

    The primary outcome is the change in self-reported pain intensity from baseline (prior to the first Scrambler Therapy session) to the post-final Scrambler Therapy session as measured by Numerical Rating Scale (NRS) or Wong-Baker Faces Pain Scale. The patients will rate pain using one of these scales at the beginning and the end of each treatment session with the primary comparison between the pre-first treatment session and the post-final treatment session. Total score range from 0-10, for both scales with a higher score indicating more pain.